Today: 21 January 2026
Subscribe
Browse Category

NASDAQ:MRNA News 20 January 2026 - 21 January 2026

Merck (MRK) stock ends higher on long-term Keytruda cancer-vaccine data; Guardant pact and earnings ahead

Merck (MRK) stock ends higher on long-term Keytruda cancer-vaccine data; Guardant pact and earnings ahead

New York, Jan 20, 2026, 20:41 EST — Market closed. Merck & Co’s stock ended Tuesday 0.57% higher, closing at $109.45, supported by long-term data on a personalized melanoma vaccine it’s working on with Moderna, which helped steady investor sentiment as the session wrapped up. (Finviz) The update is crucial as Merck aims to expand its growth story beyond Keytruda,…
21 January 2026
·······
Merck stock barely budges after five-year Moderna vaccine data keeps Keytruda trade in play

Merck stock barely budges after five-year Moderna vaccine data keeps Keytruda trade in play

New York, January 20, 2026, 14:02 EST — Regular session Merck & Co (MRK.N) shares held steady on Tuesday following news that the company’s personalized cancer vaccine, developed with Moderna, continued to lower the risk of melanoma recurrence and death when used alongside Keytruda (pembrolizumab). By 2:02 p.m. EST, Merck was down just 0.01% at $108.82, with the stock fluctuating…
20 January 2026
·····

Stock Market Today

  • Wall Street steadies after Trump dismisses forceful Greenland acquisition
    January 21, 2026, 1:50 PM EST. Wall Street steadied on Wednesday after President Donald Trump said he would not use force to take Greenland, easing recent market fears. The S&P 500 gained 0.3%, recovering from a 2.1% drop amid earlier tariff tensions. The Dow rose 188 points, or 0.4%, while the Nasdaq was mostly unchanged. Treasury yields and the U.S. dollar stabilized following recent volatility linked to inflation and global debt concerns. However, gold prices continued to rise, reflecting underlying market caution. Halliburton and United Airlines reported strong quarterly profits, bolstering the market, but gains were offset by a 4.6% decline in Netflix shares due to worries over slowing subscriber growth and a weak profit forecast. Trump's history of aggressive rhetoric followed by softer outcomes remains a key market influence.
Go toTop